Smoking Mechanics and Impact on Smoking Cessation: Two Cases of Smoking Lapse Status Post Lung Transplantation

Panagis Galiatsatos1,2, Princess Ekpo2, Raiza Schreiber1,2, Lindsay Barker3 and Pali Shah1,3

1Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Tobacco Treatment Clinic, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. 3Office of Transplantation, Johns Hopkins Hospital, Baltimore, MD, USA.

ABSTRACT

BACKGROUND: Smoking behavior includes mechanisms taken on by persons to adjust for certain characteristic changes of cigarettes. However, as lung function declines due to lung-specific diseases, it is unclear how mechanical smoking behavior changes affect persons who smoke. We review two cases of patients who stopped smoking prior to and then subsequently resumed smoking after lung transplantation.

METHODS: A retrospective review of two patients who were recipients of lung transplantation and sustained from cigarette usage prior to transplantation.

RESULTS: Patient A was a 54-year-old woman who received a double lung transplant secondary to chronic obstructive pulmonary disease (COPD) in October 2017. She had stopped smoking cigarettes in July 2015 (FEV1 .56 L). Patient B was a 40-year-old man who received a double lung transplantation due to sarcoidosis in January 2015. He stopped smoking cigarettes in February 2012 (FEV1 1.15 L). Post-transplant, Patient A resumed smoking on March 2018 where her FEV1 was at 2.12 L (5 months post-transplantation), and Patient B resumed smoking in April 2017 where his FEV1 was 2.37 L (26 months post-transplantation).

CONCLUSION: We report on two patients who resumed smoking after lung transplantation. While variations of smoking mechanics have been identified as a function of nicotine yield and type of cigarette, it lung mechanics may play a role in active smoking as well. Therefore, proper screening for tobacco usage post-lung transplantation should be considered a priority in order to preserve transplanted lungs.

KEYWORDS: Lung transplant, smoking cessation, tobacco dependence, relapse, smoking topography

Introduction

Smoking behavior is distinct, highly complex, and dynamic.1 Smoking topography attempts to characterize an individual’s smoking behavior holistically, addressing cigarette properties, smoking mechanics, and triggers.2-4 Topography parameters have been utilized to exhibit the compensatory smoking behavior resulting from cigarette brand-switching. Participants regulated their nicotine intake by smoking more of the low-yield cigarettes in comparison to the high-yield cigarettes.5-7 It remains unclear, though, what part of smoking topography is a significant driver in consumption rate and/or abstinence for certain populations of active smokers.

Smoking mechanics is a part of smoking topography involving parameters for puffing, inhalation, and exhalation.8,9 The inhalation and exhalation parameters of smoking mechanics depend, in part, on the condition of airways and lung tissue. Airway strength can be measured with forced expiratory volume (FEV1) and forced vital capacity (FVC). While smoking has been shown to reduce variables such as FEV1,8,9 it is unclear if such changes impact smoking continuation and/or cessation or overall smoking topography. It is possible that patients with diminished lung function may smoke less of a cigarette due to mechanical limitations, suggesting an interplay between smoking mechanics and lung health.

Lung transplantation is currently a treatment option for those with end-stage lung diseases.10 For lung transplant candidates, active smoking is a contraindication to transplant, and many centers recommend a period of abstinence from smoking prior to waitlisting.11,12 Around 40% are active smokers before approaching lung transplantation candidacy.13 Unfortunately, smoking cessation therapy compliance of transplant recipients is low, with 10–40% relapsing post-lung transplantation.13,14 The role of smoking mechanics in...
successful smoking cessation and smoking relapse in post-lung transplant patients has yet to be determined.

In this study, we present the cases of two patients with tobacco dependence who received lung transplants after maintaining smoking abstinence, though relapsed to tobacco usage after transplantation. We discuss in detail how changes in their lung function affected their smoking mechanics and may have impacted their relapse to smoking.

Methods
For both patients, we collected several variables to better understand their smoking phenotype. This included brand of cigarette, smoking topography (variables of smoking mechanics such as puff duration, inhalation duration, and puffs per cigarette), and triggers to smoking. Further, we identified the age that they began to smoke consistently (defined as daily use of cigarettes) as well prior quit attempt strategies and duration of abstinence from smoking. The study was approved by Institutional Review Board at Johns Hopkins School of Medicine (IRB00282725) and all actions undertaken by the authors were in accordance with the Declaration of Helsinki, along with written consent for both patients.

Screening for smoking cessation at our institution takes on both self-report and laboratory data. Specifically, we screen for urine nicotine and cotinine. If the patient is using nicotine replacement therapies (NRT) to assist in smoking cessation, then we screen for anabasine to assure the nicotine and cotinine are from an NRT source and not tobacco products. Pre-transplantation, the aforementioned laboratory data is monitored until the patient achieves a status of 6-months smoke-free. For patients who are post-lung transplant, since there are no active international guidelines suggesting how to monitor for smoking relapse, at our institution we continue to assess smoking status with self-reports and with the aforementioned smoking-related biomarkers. These biomarkers are ordered at the discretion of the transplant team in conjunction with clinical assessments of the patient.

We collected data on their pulmonary-specific morbidity, as well as any other morbidity that would influence the patient’s tobacco dependence (e.g., major depressive disorder and general anxiety disorder). In regards to the patient’s pulmonary-specific morbidity, we documented management strategies prior to pre-transplantation, pulmonary function testing, and management of tobacco dependence. Post-transplantation, we collected data on ongoing management of the patient’s tobacco dependence and pulmonary function testing. Finally, we selected patients who relapsed into smoking post-lung transplant and, after confirmation of their smoking resumption, were enrolled into the Tobacco Treatment Clinic at the Johns Hopkins University School of Medicine.

Results
Patient A
Patient A is a 54-year-old woman status post a double lung transplant secondary to chronic obstructive pulmonary disease (COPD). The date of transplant was October 2017. Her COPD was considered a GOLD Class D given her exacerbation history, and was managed with an inhaled long-acting muscarinic antagonist, inhaled corticosteroid, inhaled long-acting beta2 agonists, as well as chronic macrolide (azithromycin), and an as needed short-acting beta2 agonist inhalers and nebulizers. She also underwent pulmonary rehabilitation for her COPD management as well. Given the inability to improve her symptoms as well as her overall prognosis, the patient began to pursue candidacy for lung transplantation.

Patient A quit smoking in 2015, with an FEV1 at the time of .56 L (21% predicted). She used varenicline to help with her smoking cessation strategy in 2015. She discussed that she has been smoking since the age of 15, and smoked consistently a pack of cigarettes a day, if not more, up until her early 40s. When she was diagnosed with COPD in 2004, she found herself frequenting hospitalizations and outpatient clinics due to exacerbations, often making it difficult to smoke given her “breathlessness.” She discussed her smoking mechanics as long puffs, deep inhalations, as well as taking more than 5 puffs per cigarette (Table 1). Her choice of cigarette usage is Marlboro Reds, smoking a pack or more a day. She identified triggers to smoking as stress and anxiety, specific places (e.g., bathrooms of her home and her car), and after food. She never attempted to quit in the past, but did have periods without smoking, often due to COPD-related health issues. For the purpose of obtain a lung transplant, she was started on varenicline, using the medication for 6-weeks in total, stopping in July 2015 and receiving a transplant in 2017.

Patient A discussed a lapse in smoking at 5-months post-transplantation after identification of a positive urine nicotine and cotinine level, sent at the discretion of the transplant team given a decline of lung function on pulmonary function testing.

Table 1. Patient characteristics and smoking topography.

|                  | PATIENT A | PATIENT B |
|------------------|-----------|-----------|
| FEV1* (time of smoking cessation) | .56 L (21%) | 1.15 L (35%) |
| Smoking history  |           |           |
| Age of smoking onset | 14 years old | 12 years old |
| Cigarette preference | Marlboro reds | Newport slims |
| Packs per year   | 80        | 30        |
| Puff duration    | Long      | Long      |
| Inhalation hold  | Long      | Long      |
| Puffs per cigarette | >5        | >5        |
| Cigarettes per day | 10–15    | 15–20     |
| Quit strategy    | Varenicline | Avoidance |
| FEV1 (time of smoking relapse) | 2.12 (70%) | 2.37 (72%) |
| Relapse time     | 5-months  | 26-months |
| Post-transplant  |           |           |

*FEV1 = Forced expiratory volume, 1-second.
The patient highlighted that stress at that time influenced significantly the need to re-engage with smoking. The ability to smoke in the manner she was accustomed to (long puffs, long inhalation) reaffirmed as well a “satisfaction” gain from smoking. At the time of relapse, her FEV1 had increased to 2.12 L, an over 200% increase in FEV1 from the patient’s prior baseline when she began to abstain from cigarettes.

**Patient B**

Patient B is a 40-year-old man status post a double lung transplant secondary to sarcoidosis. The date of transplant was January 2015. The impact of sarcoidosis on the patient’s lungs was severe, with pre-transplant imaging identifying extensive central bronchiectasis, interstitial lung disease present with predominance near hila and upper lobes. Further, there was a cavitary lesion in the right upper lobe as well. Patient B was managed mainly with prednisone and short-acting beta agonist inhalers, though he had frequent hospitalizations for his sarcoidosis and resulting pulmonary symptoms of dyspnea. As his disease progressed, he discussed his ability to breathe was a challenge, even at rest, coupled with excessive sputum production. Both of these symptoms impaired his ability to smoke, ultimately resulting in his abstinence transition.

Patient B began to smoke at the age of 12. His preferred cigarette choice was Newport Slims, smoking up to a pack of cigarettes a day. He described his smoking mechanics as long puffs with a long inhalation, and would smoke the cigarette completely (Table 1). He identified his triggers to smoke as stress and anxiety, after eating, and certain areas (e.g., in his car). He eventually stopped smoking, identifying while he wanted a cigarette, and number of puffs per cigarette. Further, the nicotine itself from cigarette smoke may provide a positive consequence for a person actively smoking. For instance, in anxiety disorders may increase smoking behavior and the risk for nicotine dependence, as cigarettes may be seen as an anxiolytic self-treatment. Both patients’ description of their smoking mechanics, specifically their puff duration and inhalation hold (puff volume), appeared to be impacted by specific external influences (stress and anxiety). When faced with these triggers to smoke in the past, during low FEV1 variables, their inability to smoke in the manner they desired resulted in the ability to pursue abstinence. However, while faced with the same triggers post-transplant, the ability to match their desired smoking mechanics due to the improved FEV1 to the trigger that is driving their craving for nicotine (anxiety and stress) resulted in a lapse to cigarette consumption.

A significant insight into the lapse of smoking by both patients’ status post-post-lung transplantation is in how it reaffirms tobacco dependence and nicotine addiction as a chronic disease. For instance, proteins impacting tolerance and craving in nicotine addiction, specifically cAMP response element-binding protein (CREB) and delta fos b, remain elevated after an individual’s last cigarette for a significant amount of time (if not permanent). Both proteins play a significant role in nicotine’s ability to impact the brain’s reward system as well as the conditioning that occurs in regards to person’s compulsion towards smoking. Further, if nicotine exposure occurs at a young age, at a time when the prefrontal cortex continues to evolve, epigenetic changes may sensitize the brain to nicotine craving and future and continued use of cigarettes. This is the case for both patients, who began smoking while they were adolescents. Therefore, insight into both active smoking topography as well as past usage of cigarettes (e.g., age of initiation of smoking) may result in an understanding of a smoking phenotype that warrants management both before and after lung transplantation.

Smoking resumption post solid organ transplant is not an uncommon diagnosis in transplant centers. In regards to post-lung transplantation, smoking resumption has been reported from 0 to 10% in the United States to up to 15% at a European transplant center. Smoking cessation and smoking relapse are both complex, with multiple factors contributing to cessation and relapse. Improved lung function is an exceptional outcome for patients after lung transplantation, one that aims to improve a person’s quality of life. However, the challenge with improved lung function is it may also contribute to smoking resumption, a plausible parallel since the opposite, a decreased lung function resulting in smoking cessation, was confirmed in our case series. Therefore, as Hofmann et al. underscore with their conclusion...
of smoking resumption in post-transplant patients is likely underestimated, we believe our case series adds to the necessity of smoking resumption in post-transplant patients. The management, like other chronic diseases, warrants consistent reassessments. We believe the aforementioned cases emphasize the need for international guidelines to offer recommendations on screening for smoking resumption post-lung transplantation and availability of immediate resources to help patients if they should relapse in an effort to preserve transplanted lungs.

**REFERENCES**

1. Jamner LD, Whalen CK, Loughlin SE, et al. Tobacco use across the formative years: a road map to developmental vulnerabilities. *Nicotine Tob Res*. 2003;5(suppl 1):S71-S87.
2. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens cigarettes on exposure to tar, nicotine, and carbon monoxide. *Eur J Respir Dis Suppl*. 1986;147-153.
3. Strasser AA, Pickworth WB, Patterson F, Lerman C. Smoking topography predicts smoking behavior as determinants of smoke exposure. *Eur J Respir Dis Suppl*. 1992;41(4):701-706.
4. Bridges RB, Humble JW, Turke JA, Rehn SR. Smoking history, cigarette yield and smoking behavior as determinants of smoke exposure. *Eur J Respir Dis Suppl*. 1986;146:129-137.
5. Kolonen S, Tuomisto J, Puustinen P, Airaksinen MM. Puffing behavior during the smoking of a single cigarette in a naturalistic environment. *Pharmacol Biochem Behav*. 1992;41(4):701-706.
6. Benowitz NL, Jacob P 3rd, Kozlowski LT, Yu L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. *N Engl J Med*. 1986;315(21):1310-1313.
7. Benowitz NL, Jacob P 3rd, Yu L, Takott R, Hall S, Jones RT. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. *JAMA*. 1986;256(2):241-246.
8. Anthonisen NR, Connell JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. *Am J Respir Crit Care Med*. 2002;166(5):675-679.
9. Murray RP, Connell JE, Rand CS, Pau W, Anthonisen NR. Persistence of the effect of the lung health study (LHS) smoking intervention over eleven years. *Proc Med*. 2002;35(4):314-319.
10. Kreider M, Kodlot RM. Selection of candidates for lung transplantation. *Proc Am Thorac Soc*. 2009;6(1):20-27.
11. Verleden GM, Dupont LJ, Van Raemdonck DE, Vos R, Vanhaecke B, M. Leuven Lung Transplant Group. Lung transplantation: a 15-year single-center experience. *Clin Transpl*. 2007,121-130.
12. Dew MA, DiMartini AF, Dobbels F, et al. The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term mechanical circulatory support. *Psychosomatics*. 2018;59(5):415-440.
13. Vos R, De Vusser K, Schaevers Y, et al. Smoking resumption after lung transplantation: a sobering truth. *Eur Respir J*. 2010;35(6):1411-1413.
14. Cohert C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. *Transplantation*. 2012;94(10):979-987.
15. Jacob P 3rd, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. *Cancer Epidemiol Biomarkers Prev*. 2002;11(12):1668-1673.
16. Hofmann P, Benden C, Kohler M, Schuurmans MM. Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management. *J Thorac Dis*. 2018;10(7):4609-4618.
17. Warburton DM. Smoking with reason. *J Smok Relat Disord*. 1992;2:55-59.
18. Paton GC, Carlin J, Coffer C, Wolfe R, Hibbert M, Bowes G. Depression, anxiety, and smoking initiation: a prospective study over 3 years. *Am J Public Health*. 1998;88(10):1518-1522.
19. Tjora T, Hetland J, Aare L, Overland S. Distal and proximal family predictors of adolescents’ smoking initiation and development: a longitudinal latent curve model analysis. *BMC Publ Health*. 2011;11:911.
20. Pandy SC, Roy A, Xu T, Mittal N. Effects of protracted nicotine exposure and withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat brain. *J Neurochem*. 2001;77(3):943-952.
21. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. *Proc Natl Acad Sci USA*. 2001;98(20):11042-11046.
22. Gotoinova NA, Mansvelder HD. Short- and long-term consequences of nicotine exposure during adolescence for prefrontal cortex neuronal network function. *Cold Spring Harb Perspect Med*. 2012;2(12):a012120.
23. Baudolff GS, Holloman CH, Carter S, Pope-Harman AL, Nunley DR. Cigarette smoking following lung transplantation: effects on allograft function and recipient functional performance. *J CardiopoIm Rehabil Prev*. 2015;35(2):147-153.
24. Zmeskal M, Kralikova E, Kurcova I, et al. Continued smoking in lung transplant patients: a cross sectional survey. *Eur Respir J*. 2016;55(1):29-35.